Who makes Depobupivacaine?

Depobupivacaine is developed by The Cleveland Clinic.

What development phase is Depobupivacaine in?

Depobupivacaine is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Depobupivacaine

The Cleveland Clinic · FDA-approved active Small molecule Quality 1/100

At a glance

Generic name	Depobupivacaine
Also known as	Exparel
Sponsor	The Cleveland Clinic
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Comparison of Local Anesthetic Infusion Pump Versus Depofoam Bupivacaine for Pain Management (PHASE4)
Study to Evaluate Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy (PHASE3)
A Phase 3 Study to Evaluate the Safety and Efficacy of SKY0402 in Subjects Undergoing Total Knee Arthroplasty (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Depobupivacaine CI brief — competitive landscape report
Depobupivacaine updates RSS · CI watch RSS
The Cleveland Clinic portfolio CI